Trastuzumab Pamirtecan Provides Meaningful Survival Benefit in Pretreated HER2-Expressing Endometrial Cancer OncLive
Deep endometriosis (DE) is the most severe subtype of endometriosis, marked by aggressive cellular behavior and debilitating pain. However, the molecular mechanisms underlying DE pathogenesis remain poorly understood. In this …
Endometriosis (EM) and chronic endometritis (CE) are both implicated in female infertility, yet the relationship between them remains incompletely understood. In this narrative review, we synthesize non-systematically selected clinical and …
Endometriosis is a complex, multicompartmental disease in which accurately conveying the extent of involvement to the surgical team is essential for preoperative planning and patient counseling. In this context, medical …
Estrogen stimulates corticotropin-releasing hormone (CRH) expression in endometrial tissue, and CRH signaling contributes to inflammation and pain, suggesting a mechanistic role in endometriosis pathophysiology. We previously identified elevated CRH receptor-1 …
Nerve Growth Factor (NGF), a member of the neurotrophin family, is currently regarded as a key regulator of ovarian physiology beyond its well-known neurotrophic functions. The mammalian ovary is one …
Endometriosis is a chronic, estrogen-dependent, and heterogeneous gynecologic disorder associated with persistent pain, infertility, and substantial impairment in quality of life (QoL), necessitating individualized and evidence-based management. This narrative review …
BioNTech and DualityBio Report Clinically Meaningful Efficacy for Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer BioPharm International
BioNTech, DualityBio tout 'clinically meaningful' efficacy for ADC in mid-stage endometrial cancer trial BioSpace
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer The Manila Times